Status: Recruiting
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.
Participants needed: 50
Trial details
Phase: Phase 2Age: 18-70Biological sex: FemaleType: InterventionalSponsor: Tongji HospitalUpdated: Sep 19, 2024Locations: 2
Eligibility criteria
Clinical diagnosis of untreated stage IB cervical cancer with IB2 (FIGO, 2018 cr... [+8]
Subjects with an active, known, or suspected autoimmune disease, or a history of... [+20]